ArticleJournal of the anus, rectum and colon2026
Novel Preoperative Cancer-Specific Glasgow Prognostic Score Strongly Predicts Survival in Stage II/III Colorectal Cancer.
Article in Journal of the anus, rectum and colon, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The Glasgow Prognostic Score (GPS), derived from serum C-reactive protein (CRP) and albumin (Alb) levels, is a validated prognostic marker in colorectal cancer (CRC). However, it lacks tumor-specific components. Carcinoembryonic antigen (CEA) is indicative of tumor burden and biology. To enhance prognostic stratification, we developed the Cancer-Specific Glasgow Prognostic Score (C-GPS), which integrates GPS with CEA. Methods: We retrospectively analyzed 753 patients with Stage II/III CRC who underwent curative resection between 2008 and 2018. The C-GPS was calculated by assigning one point each for CEA >5.0 ng/mL, Alb <3.5 g/dL, and CRP >1.0 mg/dL. Patients were categorized into Low (0), Mid (1-2), and High (3) C-GPS groups. Survival outcomes were evaluated using Kaplan-Meier and Cox regression models, and prognostic discrimination was assessed using the concordance index (C-index). Results: The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly lower in the High C-GPS group (62.1% and 72.7%, respectively; p<0.01). Multivariate analysis identified High C-GPS as an independent predictor of poor DFS (HR: 1.76, 95% CI: 1.01-3.10, p=0.049) and OS (HR: 1.30, 95% CI: 1.01-1.66, p=0.034). The C-GPS demonstrated superior prognostic discrimination compared to GPS for both DFS (C-index: 0.583 vs. 0.524) and OS (0.633 vs. 0.576). Conclusions: C-GPS is a simple and clinically feasible composite index that provides better prognostic accuracy than GPS by incorporating tumor burden, systemic inflammation, and nutritional status to stratify patients with CRC following curative surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.